The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 02, 2024

Filed:

Jun. 18, 2021
Applicant:

Go Therapeutics, Inc., Cambridge, MA (US);

Inventors:

Hans H. Wandall, Charlottenlund, DK;

Johannes Wirenfeldt Vad Pedersen, Valby, DK;

Eric Paul Bennett, Kgs. Lyngby, DK;

Henrik Clausen, Holte, DK;

Ulla Mandel, Holte, DK;

Assignee:

GO Therapeutics, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); C07K 16/00 (2006.01); C07K 14/47 (2006.01); C07K 14/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57484 (2013.01); C07K 14/00 (2013.01); C07K 14/4727 (2013.01); C07K 16/00 (2013.01); C07K 16/3092 (2013.01); C07K 2317/732 (2013.01);
Abstract

The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.


Find Patent Forward Citations

Loading…